AssetMark Inc
ORKA icon

AssetMark Inc’s Oruka Therapeutics ORKA Stock Holding History

AssetMark Inc’s Portfolio ORKA Stock Details ORKA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$500 Buy
+6
New +$565 ﹤0.01% 3407

Other funds holding ORKA

Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return
Candriam SCA
Candriam SCA Strassen, Luxembourg, Luxembourg $22.5B AUM 50.38% 1-Year Est. Return
SEB Asset Management
SEB Asset Management Stockholm $27B AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
ALPS Advisors
ALPS Advisors Denver, Colorado $21.8B AUM 17.58% 1-Year Est. Return
Moody Aldrich Partners
Moody Aldrich Partners Marblehead, Massachusetts $523M AUM 75.24% 1-Year Est. Return
Secure Asset Management
Secure Asset Management Troy, Michigan $753M AUM 20.9% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $195B AUM 21.17% 1-Year Est. Return
Citigroup
Citigroup New York $308B AUM 40.94% 1-Year Est. Return
Mutual of America Capital Management
Mutual of America Capital Management New York $10.1B AUM 33.74% 1-Year Est. Return

AssetMark Inc's ORKA Position: Q3 2026 in Review

AssetMark Inc opened a new position in Oruka Therapeutics (ORKA) in Q3 2026: 6 shares worth $500. The stake represents ﹤0.01% of the portfolio and ranks #3407 among its holdings.

58 funds tracked by Wall St. Rank hold ORKA as of Q3 2026.

  • AssetMark Inc held 6 shares of Oruka Therapeutics worth $500 as of Q3 2026.
  • Oruka Therapeutics was a new AssetMark Inc position in Q3 2026.
  • Oruka Therapeutics made up ﹤0.01% of AssetMark Inc's portfolio in Q3 2026, its #3407 holding.
  • 58 funds tracked by Wall St. Rank held Oruka Therapeutics as of Q3 2026.

Based on AssetMark Inc's 13F filing for Q3 2026, filed 21 Oct 2026.